Glow-in-the-Dark dye could reveal hidden heart attack risk
NCT ID NCT06957821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether a fluorescent dye called LUMISIGHT (pegulicianine) can light up inflammation in artery plaques removed during surgery. Inflammation is a key driver of heart attacks, but current imaging can't see it clearly. Researchers will compare the dye to a placebo in 25 people with severe carotid or peripheral artery disease. If the dye works, it might one day help doctors identify high-risk plaques before they cause problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pegulicianine (LUMISIGHT) dye
What this could lead to
If successful, this could lead to a new way to see dangerous inflammation in arteries, helping doctors better predict and prevent heart attacks.
What could go wrong
This is a very early, small study (25 people) testing the dye on removed tissue, not in living patients. It may not work as hoped or translate to real-time imaging.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••